HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Rapid complete remission in multiple myeloma with bortezomib/thalidomide/dexamethasone combination therapy following development of tumor lysis syndrome.

AuthorsC S Chim
JournalCancer chemotherapy and pharmacology (Cancer Chemother Pharmacol) Vol. 62 Issue 1 Pg. 181-2 (Jun 2008) ISSN: 0344-5704 [Print] Germany
PMID17846773 (Publication Type: Case Reports, Letter)
Chemical References
  • Antineoplastic Agents
  • Antineoplastic Agents, Hormonal
  • Boronic Acids
  • Pyrazines
  • Thalidomide
  • Bortezomib
  • Dexamethasone
  • L-Lactate Dehydrogenase
Topics
  • Antineoplastic Agents (administration & dosage)
  • Antineoplastic Agents, Hormonal (administration & dosage)
  • Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use)
  • Boronic Acids (administration & dosage)
  • Bortezomib
  • Dexamethasone (administration & dosage)
  • Female
  • Humans
  • L-Lactate Dehydrogenase (blood)
  • Middle Aged
  • Multiple Myeloma (complications, drug therapy)
  • Pyrazines (administration & dosage)
  • Thalidomide (administration & dosage)
  • Tumor Lysis Syndrome (complications)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: